Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response.

BACKGROUND Efficacy of infliximab in Crohn's disease (CD) showed by randomized controlled trials must be confirmed in clinical practice. We aimed to evaluate efficacy and safety of infliximab in CD patients of the Madrid area, looking for clinical predictors of response. METHODS Multicenter retrospective survey of all CD patients treated with infliximab in 8 University hospitals of the Madrid area (Spain) with a minimum follow up of 14 wks. RESULTS 169 patients included (48%males, mean age 39 +/- 12 yrs). 64% of them had perianal disease. 82% were under immunosuppressants. 1,355 infliximab infusions administered (mean 8, range 1-30). 90% response rate and 48% remission rate were obtained with induction therapy. 73% followed maintenance treatment, and 78% of them maintained or improved the response after a mean follow up of 28 months (range 3.5-86). 24 patients lost response during the follow up, after a mean of 41 wks (range 6-248). Only the prescription of maintenance therapy was predictive factor for favourable response (p < 0.01). 17 infusion reactions were reported (10% of the patients, 1.2% of the infusions; only one case was severe) and were the cause of treatment withdrawal in 7 patients. Co-treatment with immunosuppressive drugs and maintenance infliximab therapy were protective factors for infusion reactions (p < 0.05). Other adverse events occurred in 26% of the patients, and were cause of treatment withdrawal in 7 patients. CONCLUSIONS Infliximab is effective and safe for CD management but concomitant immunosuppressive drugs and maintenance treatment should be prescribed to obtain the best outcome. That confirms in a real life clinical setting the favourable results obtained in randomized clinical trials.

[1]  M. Gassull,et al.  Efficacy and safety of short‐term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open‐label, multicentre trial , 2007, Alimentary pharmacology & therapeutics.

[2]  M. Silverberg,et al.  Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  H. Tilg,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. , 2010, Journal of Crohn's & colitis.

[4]  P. Rutgeerts,et al.  Review article: infliximab therapy for inflammatory bowel disease – seven years on , 2006, Alimentary pharmacology & therapeutics.

[5]  F. Nestle,et al.  Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial , 2005, The Lancet.

[6]  J. S. Kim,et al.  [Efficacy and safety of treatment with infliximab in Crohn's disease-the experience of single center in Korea]. , 2005, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.

[7]  E. Doménech,et al.  Recomendaciones GETECCU-2005 para el uso de infliximab (Remicade®) en la enfermedad inflamatoria intestinal , 2005 .

[8]  Y. Panis.  L’approche combinée médico-chirurgicale (séton + infliximab + azathioprine) : la panacée dans les lesions anopérinéales de Crohn ? , 2005 .

[9]  L. Beaugerie,et al.  Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery , 2005, Gut.

[10]  J. Sarles,et al.  Efficacy and Tolerance of Infliximab in Children and Adolescents with Crohn’s Disease , 2004, Inflammatory bowel diseases.

[11]  B. Sands,et al.  Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  H. Tilg,et al.  Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up , 2004, European journal of gastroenterology & hepatology.

[13]  M. Bala,et al.  Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  P. Rutgeerts,et al.  Optimizing anti-TNF treatment in inflammatory bowel disease. , 2004, Gastroenterology.

[15]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[16]  J. Satsangi,et al.  An analysis of factors influencing short‐term and sustained response to infliximab treatment for Crohn's disease , 2003, Alimentary pharmacology & therapeutics.

[17]  R. Panaccione,et al.  Combined Seton Placement, Infliximab Infusion, and Maintenance Immunosuppressives Improve Healing Rate in Fistulizing Anorectal Crohn’s Disease , 2003, Diseases of the colon and rectum.

[18]  M. Peppercorn,et al.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. , 2003, Gastroenterology.

[19]  M. Badea,et al.  Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania. , 2003, Romanian journal of gastroenterology.

[20]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[21]  R. Baldassano,et al.  Safety and Steroid-Sparing Experience Using Infliximab for Crohn's Disease at a Pediatric Inflammatory Bowel Disease Center , 2003, American Journal of Gastroenterology.

[22]  J. Achkar,et al.  Predictors of response to infliximab in patients with Crohn's disease. , 2002, Gastroenterology.

[23]  J. Belaiche,et al.  Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease , 2002, American Journal of Gastroenterology.

[24]  G. Porro,et al.  Infliximab in treatment of Crohn's disease: the Milan experience. , 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[25]  E. Schoon,et al.  Effects of anti‐tumour necrosis factor‐α therapy on the quality of life in Crohn's disease , 2002, Alimentary pharmacology & therapeutics.

[26]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[27]  J. Mendoza,et al.  Infliximab treatment and prognostic factors for response in patients with Crohn's disease. , 2002, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[28]  D. Hommes,et al.  Infliximab Treatment for Crohn's Disease: One-Year Experience in a Dutch Academic Hospital , 2002, Inflammatory bowel diseases.

[29]  C. Sample,et al.  Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta. , 2002, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[30]  E. Doménech,et al.  Recomendaciones para el uso de infliximab (Remicade®) en la enfermedad de Crohn. GETECCU 2001 , 2002 .

[31]  A. Zinsmeister,et al.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.

[32]  R. Cohen.  Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. , 2001, Inflammatory bowel diseases.

[33]  W. Selby,et al.  Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor‐α, in the treatment of Crohn’s disease: is its efficacy augmented by steroid‐sparing immunosuppressive therapy? , 2001 .

[34]  P. Martreau.  [A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators]. , 2000, Gastroenterologie clinique et biologique.

[35]  G. Greenberg,et al.  A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. , 2000, The New England journal of medicine.

[36]  W. Sandborn,et al.  Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients , 2000, American Journal of Gastroenterology.

[37]  M. Kamm,et al.  Infliximab for the treatment of fistulas in patients with Crohn'S disease. , 1999, Gastroenterology.

[38]  S. V. Deventer,et al.  Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab. , 1999 .

[39]  A. Kornbluth.  Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference. , 1998, Inflammatory bowel diseases.

[40]  H. Lamb,et al.  Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. , 1998, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[41]  R. Löfberg,et al.  Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. , 1998, Gastroenterology.

[42]  B. Feagan.  Methotrexate treatment for Crohn's disease. , 1998, Inflammatory bowel diseases.

[43]  R. Modigliani,et al.  Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine , 1996, The Lancet.

[44]  M. Gerig,et al.  A controlled double blind study of azathioprine in the management of Crohn's disease. , 1995, Gut.

[45]  P. Munkholm,et al.  Disease activity courses in a regional cohort of Crohn's disease patients. , 1995, Scandinavian journal of gastroenterology.

[46]  Loyd,et al.  Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. , 1995, The New England journal of medicine.

[47]  P. Munkholm,et al.  Frequency of glucocorticoid resistance and dependency in Crohn's disease. , 1994, Gut.

[48]  B. Pasternack,et al.  Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. , 1980, The New England journal of medicine.

[49]  J. Panés,et al.  [GETECCU-2005 recommendations for the use of infliximab (Remicade) in inflammatory bowel disease]. , 2005, Gastroenterologia y hepatologia.

[50]  J. Panés,et al.  [Recommendations for the use of infliximab (Remicade) in Crohn's disease. GETECCU 2001]. , 2002, Gastroenterologia y hepatologia.

[51]  W. Selby,et al.  Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. , 2001, Internal medicine journal.